KYNTRA BIO, INC.
KYNTRA BIO, INC. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Next quarterly earnings (projected) on November 12, 2026, a projected date rather than a confirmed one. There are 3 upcoming events on record.
Cash runway is approximately 19.7 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
Across 39 concluded trials, 72% reached completion rather than being terminated or withdrawn.
| Date | Event | Type | Phase |
|---|---|---|---|
| November 12, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| March 31, 2028 | A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Trial Milestone | Phase 2 |
| September 15, 2030 | A Study to Investigate the Efficacy and Safety of Roxadustat (FG-4592) for Treating Anemia in Participants With Myelodysplastic Syndromes (MDS) | Trial Milestone | Phase 3 |
Track KYNB alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open KYNB in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.